PTK 2015 Banner 
2015 Peptalk M Banner 

Pipeline Two Icon Pipeline Two Header 

Cambridge Healthtech Institute’s 2nd Annual
Antibody-Drug Conjugates
Engineering Targeted Therapeutics
January 21-22, 2015

The therapeutic potential of antibodies is enhanced by conjugating them to small molecule drugs. This combination merges the benefits of highly potent drugs with selective binders of specific tumor antigens. Antibody-drug conjugates offer the promise of delivering more powerful tumor-killing activity while resulting in diminished side effects for cancer patients. This important Antibody-Drug Conjugates conference brings together leaders in the world of ADCs who share their R&D case studies, along with their preclinical and clinical data, to illustrate how this form of empowered antibody is transforming next-generation antibody therapeutics.

Preliminary Agenda



Examination of ADC Safety: Dose-Limiting Toxicities with ADCs 

Flavia Brunstein, M.D., Ph.D., Safety Science Leader, Lead, Safety Risk Management, Genentech, Inc. 

In vitro-in vivo Molecular Integrity of Antibody-Drug Conjugates: Applying Learning to Clinical Measurements for ADCs 

Dan Rock, Ph.D., Scientific Director, Pharmacokinetics and Drug Metabolism, Amgen, Inc.  


Mechanistic Models for Designing Efficacious ADCs  

Arijit Chakravarty, Ph.D., Senior Scientist II, Modeling and Simulation, DMPK, Takeda Pharmaceuticals  

Ags67e, an Anti-Cd37 Monomethyl Auristatin E Antibody (MMAE) Drug Conjugate as a Potential Therapeutic 

Daniel S. Pereira, Ph.D., Senior Director, Discovery Research, Agensys, Inc., an Affiliate of Astellas Pharma, Inc.  

Novel Bifunctional Linkers for the Synthesis of Homogeneous ADCs 

David Jackson, Ph.D., Principal Scientist, Igenica, Inc. 


An EGFR Targeting Antibody-Drug Conjugate Engineered for Increased Tumor Specificity  

Christopher D. Thanos, Ph.D., Director, New Molecular Entities, Halozyme Therapeutics, Inc. 

Brain-Penetrant Peptide-ADC Conjugates Reduce Tumor Size and Increase Survival in Mice with HER2-Positive Brain Tumors 

Jean Lachowicz, Ph.D., CSO, Angiochem, Inc. 


Building Effective ADCs: Selecting the Right Target, Antibody and Payload 

Adeela Kamal, Ph.D., Associate Director, Oncology Research, MedImmune, LLC 

Innovative Payload Platform Powers ADC Development 

John Lambert, Ph.D., Executive Vice President and CSO, ImmunoGen, Inc.  

Delivery of Potent Cytotoxins as ADC Payloads 

Vishal Verma, Ph.D., Scientist, Genentech, Inc. 

Best-in-Class ADCs; Homogeneity is Necessary but Not Sufficient - Selection of Optimal Conjugation Site is Paramount 

Trevor Hallam, Ph.D., CSO, Sutro Biopharma, Inc.